Congeni B L
Antimicrob Agents Chemother. 1984 Jan;25(1):40-4. doi: 10.1128/AAC.25.1.40.
Forty-five children (aged 1 day to 15 years) with bacterial meningitis were randomized to receive either traditional therapy (ampicillin and chloramphenicol or gentamicin, pending sensitivity) or ceftriaxone (100 mg/kg per day in two doses for a minimum of 10 days). The etiological agents involved were similar for the two groups and included Haemophilus influenzae type b, Neisseria meningitidis, Streptococcus pneumoniae, and group B streptococcus. Repeat spinal taps were carried out 24 to 48 h after admission. Organisms were seen on the Gram stain of one patient treated with ceftriaxone, but five patients in the traditional therapy group had organisms present on Gram stain of uncentrifuged spinal fluid or positive cultures of the spinal fluid (or both). Ceftriaxone entered the cerebrospinal fluid well, and the average cerebrospinal fluid bactericidal activity for ceftriaxone 1 h after a dose was at least 60 times greater than for ampicillin or chloramphenicol. In those patients who received treatment for a long enough period of time to permit evaluation, there was one death in each group, both due to S. pneumoniae. The length of fever and complications were similar for the patients in both groups. Ceftriaxone was well tolerated; diarrhea, seen in 5 of the 22 patients who received the drug, was the most commonly encountered adverse effect. It was mild, and in no case was it necessary to discontinue the drug. Ceftriaxone appears in this preliminary study to be a safe and acceptable single agent for the treatment of bacterial meningitis in children.
45名患有细菌性脑膜炎的儿童(年龄从1天至15岁)被随机分组,分别接受传统疗法(氨苄青霉素和氯霉素或庆大霉素,根据药敏结果而定)或头孢曲松(每日100mg/kg,分两次给药,至少用药10天)。两组涉及的病原体相似,包括b型流感嗜血杆菌、脑膜炎奈瑟菌、肺炎链球菌和B组链球菌。入院后24至48小时进行重复腰椎穿刺。接受头孢曲松治疗的1例患者的革兰氏染色中发现了病原体,但传统治疗组有5例患者在未离心的脑脊液革兰氏染色或脑脊液培养(或两者)中发现有病原体。头孢曲松能很好地进入脑脊液,给药1小时后头孢曲松的平均脑脊液杀菌活性至少比氨苄青霉素或氯霉素高60倍。在那些接受了足够长时间治疗以便进行评估的患者中,两组各有1例死亡,均由肺炎链球菌所致。两组患者的发热时长和并发症情况相似。头孢曲松耐受性良好;接受该药治疗的22例患者中有5例出现腹泻,这是最常见的不良反应。腹泻症状较轻,无一例需要停药。在这项初步研究中,头孢曲松似乎是治疗儿童细菌性脑膜炎的一种安全且可接受的单一药物。